Exosomes Derived from BMSCs Ameliorate Intestinal Ischemia–Reperfusion Injury by Regulating miR-144-3p-Mediated Oxidative Stress

Zhang, Guangru; Wan, Zhanhai; Liu, Zhenzhen; Liu, Disheng; Zhao, Zhiyu; Leng, Yufang

doi:10.1007/s10620-022-07546-0

Cited by 14 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxidative stress is strongly correlated with cellular injury, and involved in the onset of several pathologies, including IRI [ 39 , 40 ]. Growing evidence supports the hypothesis that MSCs exert antioxidant properties in several pathological processes, which may explain MSCs’ cytoprotective properties in IRI experimental models [ 41 , 42 ]. These cells have been extensively tested in different areas of therapeutic application, including organ transplantation [ 43 , 44 ], where the beneficial strategies are aimed at reducing IRI and acute inflammatory responses ( Table 1 ).…”

Section: Mesenchymal Stem/stromal Cell (Msc)-based Therapy As a New S...mentioning

confidence: 87%

“…In vivo experiments have shown that MSC-derived exosomal miR-34a/c-5p, and miR-29b-3p improved the intestinal barrier, thus alleviating intestinal IRI via the Snail/claudin pathway [ 195 ]. Recently, it was reported that BM-MSC EXOs can alleviate intestinal IRI through the PTEN/Akt/Nrf2 pathway by targeting miR-144-3p [ 42 ].…”

Section: Mesenchymal Stem/stromal Cell (Msc)-based Therapy As a New S...mentioning

confidence: 99%

See 1 more Smart Citation

Role of Mesenchymal Stem/Stromal Cells in Modulating Ischemia/Reperfusion Injury: Current State of the Art and Future Perspectives

et al. 2023

View full text Add to dashboard Cite

Ischemia/reperfusion injury (IRI) is a multistep damage that occurs in several tissues when a blood flow interruption is inevitable, such as during organ surgery or transplantation. It is responsible for cell death and tissue dysfunction, thus leading, in the case of transplantation, to organ rejection. IRI takes place during reperfusion, i.e., when blood flow is restored, by activating inflammation and reactive oxygen species (ROS) production, causing mitochondrial damage and apoptosis of parenchymal cells. Unfortunately, none of the therapies currently in use are definitive, prompting the need for new therapeutic approaches. Scientific evidence has proven that mesenchymal stem/stromal cells (MSCs) can reduce inflammation and ROS, prompting this cellular therapy to also be investigated for treatment of IRI. Moreover, it has been shown that MSC therapeutic effects were mediated in part by their secretome, which appears to be involved in immune regulation and tissue repair. For these reasons, mediated MSC paracrine function might be key for injury amelioration upon IRI damage. In this review, we highlight the scientific literature on the potential beneficial use of MSCs and their products for improving IRI outcomes in different tissues/organs, focusing in particular on the paracrine effects mediated by MSCs, and on the molecular mechanisms behind these effects.

show abstract

Section: Mesenchymal Stem/stromal Cell (Msc)-based Therapy As a New S...mentioning

confidence: 87%

Section: Mesenchymal Stem/stromal Cell (Msc)-based Therapy As a New S...mentioning

confidence: 99%

Role of Mesenchymal Stem/Stromal Cells in Modulating Ischemia/Reperfusion Injury: Current State of the Art and Future Perspectives

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Additionally, the oxygen and glucose deprivation/reperfusion drastically decreased the exosomes carrying miR-144-3p, and miR-144-3p directly targets PTEN to control its expression. 259 BMSC-derived exosomes containing lncRNA were cultured with HL-1 mouse cardiomyocytes that had been subjected to hypoxia/reoxygenation (H/R). By regulating cell proliferation, elevating glutathione (GSH) content, and lowering iron ion concentration, reactive oxygen species level, and ferroptosis marker protein levels, Mir9-3hg inhibits cardiomyocyte ferroptosis in ischemia-reperfusion mice via the Pum2/PRDX6 axis.…”

Section: Role Of Msc-exos In Cardiovascular Diseasesmentioning

confidence: 99%

Biogenesis, Composition and Potential Therapeutic Applications of Mesenchymal Stem Cells Derived Exosomes in Various Diseases

Yuan¹,

Wang²,

Zhang³

et al. 2023

IJN

View full text Add to dashboard Cite

Exosomes are nanovesicles with a wide range of chemical compositions used in many different applications. Mesenchymal stem cell-derived exosomes (MSCs-EXOs) are spherical vesicles that have been shown to mediate tissue regeneration in a variety of diseases, including neurological, autoimmune and inflammatory, cancer, ischemic heart disease, lung injury, and liver fibrosis. They can modulate the immune response by interacting with immune effector cells due to the presence of anti-inflammatory compounds and are involved in intercellular communication through various types of cargo. MSCs-EXOs exhibit cytokine storm-mitigating properties in response to COVID-19. This review discussed the potential function of MSCs-EXOs in a variety of diseases including neurological, notably epileptic encephalopathy and Parkinson’s disease, cancer, angiogenesis, autoimmune and inflammatory diseases. We provided an overview of exosome biogenesis and factors that regulate exosome biogenesis. Additionally, we highlight the functions and potential use of MSCs-EXOs in the treatment of the inflammatory disease COVID-19. Finally, we covered a strategies and challenges of MSCs-EXOs. Finally, we discuss conclusion and future perspectives of MSCs-EXOs.

show abstract

“…The intestinal tract is the main immune defense barrier which is composed of the mucosal immune system and intestinal epithelial cells (IECs). Exosomes has key physiological and pathological implications on gut-related diseases, such as Inflammatory Bowel Disease (IBD) [ 83 – 86 ], colitis [ 87 , 88 ], Colorectal Cancer (CRC) [ 89 – 93 ], Necrotizing enterocolitis (NEC) [ 94 – 97 ], and intestinal ischemia and reperfusion (IR) injury [ 98 – 100 ]. Mammalian milk is rich in exosomes, which play key roles in intestinal development, prevention of excessive inflammation, maintenance of intestinal epithelium integrity, and can also be used for disease treatment [ 101 – 105 ].…”

Section: Therapeutic Effects Of Milk-derived Exosomes On Intestinal D...mentioning

confidence: 99%

“…NLRX1/FUNDC1/NIPSNAP1-2 axis mediated mitophagy [ 180 ], live kinase B1 (LKB1)/AMPK mediated autophagy [ 181 ], and mtDNA-STING pathway [ 182 ] were reported as key mechanisms in the pathogenesis of intestinal I/R injury. Bone marrow mesenchymal stem cell-derived exosomes were found to ameliorate the intestinal I/R via the miR-144-3p-mediated oxidative stress and the phosphatase and tensin homolog (PTEN)/Akt/nuclear factor E2-related factor 2 (Nrf2) pathway [ 98 ], and also regulate the immune responses and attenuate neuronal apoptosis [ 183 ] and intestinal I/R injury-induced lung injury via the TLR4/NF-κB pathway [ 184 ]. During the intestinal I/R injury, gut-derived exosomes induce liver injury by promoting hepatic M1 macrophage polarization [ 185 ], mediate memory impairment by activating microglia [ 186 ].…”

Section: Therapeutic Effects Of Milk-derived Exosomes On Intestinal D...mentioning

confidence: 99%

Potential therapeutic effects of milk-derived exosomes on intestinal diseases

Cui,

Amevor,

Zhao

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Exosomes are extracellular vesicles with the diameter of 30 ~ 150 nm, and are widely involved in intercellular communication, disease diagnosis and drug delivery carriers for targeted disease therapy. Therapeutic application of exosomes as drug carriers is limited due to the lack of sources and methods for obtaining adequate exosomes. Milk contains abundant exosomes, several studies have shown that milk-derived exosomes play crucial roles in preventing and treating intestinal diseases. In this review, we summarized the biogenesis, secretion and structure, current novel methods used for the extraction and identification of exosomes, as well as discussed the role of milk-derived exosomes in treating intestinal diseases, such as inflammatory bowel disease, necrotizing enterocolitis, colorectal cancer, and intestinal ischemia and reperfusion injury by regulating intestinal immune homeostasis, restoring gut microbiota composition and improving intestinal structure and integrity, alleviating conditions such as oxidative stress, cell apoptosis and inflammation, and reducing mitochondrial reactive oxygen species (ROS) and lysosome accumulation in both humans and animals. In addition, we discussed future prospects for the standardization of milk exosome production platform to obtain higher concentration and purity, and complete exosomes derived from milk. Several in vivo clinical studies are needed to establish milk-derived exosomes as an effective and efficient drug delivery system, and promote its application in the treatment of various diseases in both humans and animals.

show abstract

Exosomes Derived from BMSCs Ameliorate Intestinal Ischemia–Reperfusion Injury by Regulating miR-144-3p-Mediated Oxidative Stress

Cited by 14 publications

References 43 publications

Role of Mesenchymal Stem/Stromal Cells in Modulating Ischemia/Reperfusion Injury: Current State of the Art and Future Perspectives

Role of Mesenchymal Stem/Stromal Cells in Modulating Ischemia/Reperfusion Injury: Current State of the Art and Future Perspectives

Biogenesis, Composition and Potential Therapeutic Applications of Mesenchymal Stem Cells Derived Exosomes in Various Diseases

Potential therapeutic effects of milk-derived exosomes on intestinal diseases

Contact Info

Product

Resources

About